Screening for Interventional Patients
Medical Device companies can benefit from the quantitative evaluation of CT scans to determine patient eligibility for procedures.
Custom Analyses for Clinical Trials
Pharmaceutical partnerships use Imbio’s expertise in imaging biomarkers to enhance drug development and deliver more personalized care.
Why Choose Imbio As Your Imaging Partner
Companion Imaging supports medical device, biotech, and pharmaceutical companies, and their product offerings
Quantitative CT data from Imbio outputs can empower research, clinical trials, and clinical decisions across the entire patient care path.
- Automated screening for patients with specific disease phenotypes
- Better patient selection for treatments including devices or medications
- Interventional treatment planning
- Drug development
- Clinical trials and response to therapies